SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global small molecule API market was valued at US$ 126.6 million in 2017, and is projected to exhibit a CAGR of 9.1% over the forecast period (2018–2026).
Key Trends and Analysis of the Small Molecule API Market:
Several active pharmaceutical ingredients manufacturers are expanding their presence across the globe. The active pharmaceutical ingredients (API) manufacturers are establishing their commercial production units in Asia to remain competitive and gain advantage over other competitors. Furthermore, in October 2017, active pharmaceutical ingredients manufacturers Alcami, originally based in the U.S., opened an office in Tokyo, Japan, as part of its effort to expand drug development and manufacturing presence in Japan.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2423
Market players are actively focused on mergers and acquisitions, facility expansion to enhance the market share. For instance, in March 2019, GHO Capital, the European healthcare investor acquired a majority stake in Sterling Pharma Solutions, a manufacturer of small molecule APIs. Furthermore, in 2017, CordenPharma, a contract development manufacturing organization (CDMO) invested US$ 4.1 million in the manufacturing site infrastructure of its CordenPharma Switzerland facility, thereby enhancing small molecule API development capacity.
North America holds a dominant position in the global small molecule API market, owing to expansion strategies adopted by small molecule API manufacturers. For instance, in 2017, Avista Pharma Solutions, a small molecule API manufacturer, completed expansion of its Colorado-based small molecule API manufacturing site, Longmont.
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/small-molecule-api-market-2423
Key Market Takeaways:
- The global small molecule API market is expected to exhibit a CAGR of 9.1% during the forecast period (2018–2026), attributed to rising prevalence of diseases such as cancer, cardiovascular, and infectious diseases. For instance, according to the Centers for Disease Control and Prevention (CDC), 2014, around 1.5 million cases of invasive cancer, including around 15,000 cases among children younger than 20 years, and over 590,000 deaths from cancer were registered in the U.S.
- Moreover, in January 2019, Cambrex Corporation, a manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs) acquired Avista Pharma Solutions, a contract manufacturing organization from Ampersand Capital Partners. The acquisition is expected to provide Cambrex the access to its manufacturing facilities.
- Key players operating in the global small molecule API market include Lonza, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Aesica Pharmaceuticals Ltd., Albemarle Corporation, Cambrex Corporation, BASF SE, Gland Pharma Limited, Gilead Sciences, Inc., AstraZeneca Plc., Baxter International Inc., Boehringer Ingelheim International GmbH, Celgene Corporation, Piramal Pharma Solutions, Recipharm AB, Evonik Industries AG, Glenmark Pharmaceuticals Limited, Siegfried AG, AbbVie Contract Manufacturing, Aurinia Pharmaceuticals Inc., Bayer AG, Patheon, and CordenPharma International.
Buy this report now @ https://www.coherentmarketinsights.com/insight/buy-now/2423
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
